Skip to main content

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Active, not recruiting · Phase 3 · NCT06158841

Conditions: Multiple Myeloma

At a glance

Research payments reported, 2025
$1.7M
U.S. investigators named
48
Sites paid
41
Planned or actual enrollment
421

About the trial

Sponsor
AbbVie
Tested
Etentamig (drug), Carfilzomib (drug), Pomalidomide (drug), Elotuzumab (drug), Selinexor (drug), Bortezomib (drug), Dexamethasone (drug)
Dates
Started 2024-05-19; completion 2027-12
Results posted
Not yet

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine change in disease symptoms of etentamig compared to standard available therapies in adult participants with relapsed/refractory (R/R) MM. Etentamig is an investigational drug being developed for the treatment of R/R MM. This study is broken into 2 Arms; Arm A and Arm B. In Arm A, participants will receive etentami…

From ClinicalTrials.gov, last updated 2026-08-27. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $1.7M in research payments for this study in 2025 (269 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.